

Redox Pioneer: Professor Arne Holmgren

Elias S.J. Arnér



Professor Arne Holmgren

Abstract

Dr. Arne Holmgren (Ph.D., 1968) is recognized here as a redox pioneer, because he has published at least one article on redox biology that has been cited over 1000 times and has published at least 10 articles, each cited over 100 times. He is widely known for his seminal discoveries and in-depth studies of thioredoxins, thioredoxin reductases, and glutaredoxins. Dr. Holmgren, active throughout his career at Karolinska Institutet, Sweden, has led the field of research about these classes of proteins for more than 45 years, continuously building upon his sequence determination of *Escherichia coli* thioredoxin in the late 1960s and discovery of the thioredoxin fold in the 1970s. He discovered and named glutaredoxin and he determined the structure and function of several members of these glutathione-dependent disulfide oxidoreductases. He still continues to broaden the frontiers of

knowledge of thioredoxin and glutaredoxin systems. The thioredoxin fold is today recognized as one of the most common protein folds and the intriguing complexity of redox systems, redox signaling, and redox control of cellular function is constantly increasing. The legacy of Dr. Holmgren's research is therefore highly relevant and important also in the context of present science. In a tribute to his work, questions need to be addressed toward the physiological importance of redox signaling and the impact of glutaredoxin and thioredoxin systems on health and disease. Dr. Holmgren helped lay the foundation for the redox biology field and opened new vistas in the process. He is truly a redox pioneer. *Antioxid. Redox Signal.* 15, 845–851.

Experiments carried out with the highest precision should be analyzed with an unbiased mind. Redox biology has a great future. It has always been a great inspiration to know that redox proteins have been around during evolution from the beginning of life on earth and there is yet so much to discover.

—Professor Arne Holmgren

Educational and Professional Training of Dr. Holmgren

DR. HOLMGREN WAS BORN ON DECEMBER 21, 1940, in the country side outside Katrineholm in the Södermanland region of Sweden, with his childhood farm still serving as his

summer resort. From 1960 he studied medicine at the Uppsala University, where he met Dr. Peter Reichard. Dr. Reichard, who had discovered ribonucleotide reductase, was a professor of medical chemistry at Uppsala University for about 2 years during 1961–1963 (57). Arne Holmgren, then a medical student in his 20s, joined Dr. Reichard's research group and

Reviewing Editors: *Ruma Banerjee, James Bardwell, Bob Buchanan, Gary Buettner, William Chillian, Henry Forman, Vadim Gladyshev, Anonymous, Chandan K. Sen, Roberto Sitia, and Christine Winterbourn*

Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.

Author note: The author of this biography had the privilege and pleasure of joining Dr. Holmgren as a post doc in 1994, subsequently taking over the duties of heading the biochemistry division in 2008. It is with both admiration for his work and delight due to an opportunity to acknowledge the merits of Dr. Holmgren that the author has accepted the invitation by Dr. Sen (Editor, *ARS*) to summarize the accomplishments of Dr. Holmgren—a challenging task indeed.

For a list of frequently cited articles published by Prof. Holmgren, see Supplementary Table S1, available online at www.liebertonline.com/ars.

was first given the task to characterize how B₁₂ and ATP were involved in supporting CDP reductase activity in *Escherichia coli* (36). Eventually, Holmgren discovered that *E. coli* contained less than one molecule of B₁₂ per cell, thereafter leaving the B₁₂ project to search for new venues (A. Holmgren, pers. comm.). Having finished his bachelor of medicine in 1962 and his medicine and surgery courses during 1963–1964, Holmgren moved in 1964 to the laboratory of Dr. Reichard in Stockholm at Karolinska Institutet, where Dr. Reichard then had succeeded Erik Jorpes as a professor in medical chemistry (57). Within that environment, Arne Holmgren took on the tasks of further characterizing *E. coli* thioredoxin, which had just been discovered as a reductant of ribonucleotide reductase (43). This certainly proved to become a successful choice of project. Holmgren received his Ph.D. in 1968, awarded with the highest marks for a thesis entitled “Studies on thioredoxin from *Escherichia coli* B.” Dr. Holmgren has stayed faithful to the thioredoxin field ever since and he is today recognized as its foremost authority and a genuine redox pioneer. Dr. Holmgren has remained at Karolinska Institutet throughout the remainder of his career, where he subsequently became assistant professor (*Docent*) in medical chemistry in 1969, university lecturer in 1970 (with responsibilities for the medical student training), associate professor (*Forskardocent*) in 1973, professor of medical protein chemistry and enzymology in 1983, and finally succeeding Peter Reichard as professor and chairman of biochemistry in 1991 and as director of the Medical Nobel Institute for Biochemistry in 1992. In 2008, Dr. Holmgren retired on paper, but he is still a highly active scientist leading a vibrant research group, from where many additional discoveries continue to arise.

Area of Interest in Redox Biology— The Thioredoxin and Glutaredoxin Systems

In this short article recognizing the work of Dr. Holmgren, we will reflect upon his key findings on the thioredoxin and glutaredoxin systems in particular, but we should also learn from



Photo of the author together with Dr. Holmgren, in connection with the Oxygen Club of California meeting in Santa Barbara, CA, March 2010.

his strategy of careful, patient, and thorough studies of the molecular mechanisms of these proteins. The type of meticulous biochemical work performed by Dr. Holmgren is as important as ever in this present era of popularity in high-throughput screening projects and beliefs in systems biology. Although modern approaches of high-throughput studies can certainly yield important novel insights of crucial importance for the understanding of organisms, it is probably only from work of lone, focused, curious scientists that genuine discoveries of novel molecular mechanisms can arise. The work of Dr. Holmgren should thus serve as an inspiration for any aspiring researcher who may be interested in the very details of the chemistry of life.

The very first study arising from the work of Holmgren, then working with his fellow student Lars Thelander in the group of Dr. Reichard in Uppsala, related to the effects of ATP on CDP reduction and thus the allosteric regulation of ribonucleotide reductase (36). The regulation of fidelity and activity of ribonucleotide reductase through two separate allosteric effector sites is of utmost intricacy (56) and could have caught anyone's full interest. However, Holmgren choose to focus on the thioredoxin system and this led him into his tremendously successful career in the redox biology field. He published his second paper in 1967 together with Lubert Stryer and Peter Reichard on the conformational change of thioredoxin upon its reduction (61)—an important property of the protein, considering that the redox status-related conformational changes of thioredoxin are today known to affect its binding to master control factors such as apoptosis regulating kinase-1 (49). In his third to seventh papers, thus completing his Ph.D. thesis work, Holmgren worked out a reproducible scheme to prepare thioredoxin from *E. coli* cells, and by having spent time in Dr. Richard Perham's laboratory in Cambridge, England, to learn sequencing techniques, he determined the amino acid sequence of *E. coli* thioredoxin (17–19, 34, 35). The knowledge of the sequence of *E. coli* thioredoxin and the mapping of its active site -Trp-Cys-Gly-Pro-Cys-laid the very foundation for the whole thioredoxin field. Holmgren subsequently spent more than 2 years crystallizing thioredoxin and, together with Dr. Carl-Ivar Brändén, published in 1975 the 2.8 Å structure of oxidized *E. coli* thioredoxin (37). It should be noted that the thioredoxin fold is today known as one of the most utilized folds among proteins, catalyzing a wide range of important functions (1b). With the many thioredoxin fold proteins exerting highly diverse reactions within different subcellular compartments and under different conditions, clearly there must be individual protein-specific features of each particular member of this superfamily of proteins. Still, many aspects of the thioredoxin fold proteins are rather universal, and by learning from the key findings of Dr. Holmgren, we can learn much of these specific properties of the thioredoxin fold proteins and the many systems within which they act. Three of his key findings shall be summarized here in slightly more detail.

Description of Key Finding 1

The discovery of glutaredoxin and characterization of glutaredoxin systems

A major contribution of Dr. Holmgren was achieved already during his graduate studies, as was described earlier,

that is, the determination of the *E. coli* thioredoxin primary sequence. However, the two first major awards that he received, the Svedberg Prize (1979) and the Eric K. Fernström Prize (1980), recognized his discovery of *E. coli* glutaredoxin. His discovery rose from a thorough analysis of the mechanisms by which a strain of *E. coli* (tsnC7004) shown to lack thioredoxin could actually grow, thus suggesting that a second reducing system for ribonucleotide reductase existed. Through this work, a heat-stable protein that could support ribonucleotide reductase, required glutathione, and clearly was not thioredoxin was discovered by Dr. Holmgren. He named the protein "glutaredoxin" in the first description of this study, published by Holmgren as single author in 1976 (20). Early follow-up studies revealed the presence of similar glutaredoxin-like proteins also in T4 phage-infected *E. coli* (22) and calf thymus extracts (47). Purification of the *E. coli* glutaredoxin to homogeneity revealed the specific features of its glutathione-dependent activity with ribonucleotide reductase and additional enzymatic properties, such as being a general glutathione-disulfide oxidoreductase. Interestingly, already at that time there was also evidence for large amounts of additional glutaredoxins being present in *E. coli* (23, 24). Today, it is well known from the work of Holmgren and many others that most if not all organisms express several isoforms of both thioredoxins and glutaredoxins, carrying out functions that may be either specific or complementary to each other. The major differences between glutaredoxins and thioredoxins are found in their use of glutathione. Even if both classes of proteins belong to the thioredoxin fold superfamily, glutaredoxins utilize glutathione as reductant and thereby also glutathione reductase, whereas thioredoxins are directly dependent upon thioredoxin reductases (Fig. 1). This key difference in function was evident already in the earliest work of Holmgren and has generally held true until today, even if newer findings such as mammalian Grx2 being reduced by thioredoxin reductase (40) show that there may be also a cross-talk between the glutaredoxin and thioredoxin systems.

With the glutaredoxins gaining more and more interest, based upon the many functions they carry out that are not necessarily overlapping with those of thioredoxins (14), the initial papers of Holmgren discovering and describing these proteins are truly pioneering works.


Description of Key Finding 2

Catalytic mechanisms of thioredoxins and glutaredoxins

To fully understand the functions and roles of thioredoxin and glutaredoxin (14, 28, 30), Dr. Holmgren has painstakingly studied many crucial details of their structures (6), conformational dynamics (6), substrate specificities (23, 25, 32), and several additional features of these proteins. These studies have laid the foundation for our current understanding of the catalytic mechanisms of both thioredoxins and glutaredoxins. This includes the low pK_a of the nucleophilic thiolate of the N-terminally located Cys residue in the -CXXC- active site motif typical for these proteins (10–12) and the slight but important conformational differences between reduced and oxidized species of thioredoxin that may guide the binding to other protein partners, as mentioned earlier. Importantly, Dr. Holmgren has also characterized the differences between the "dithiol" reduction mechanism for disulfide reduction supported by both thioredoxins and dithiol glutaredoxins, as well as the "monothiol" reduction mechanism seen with glutaredoxins, involving the recognition and reduction of a mixed protein-glutathione disulfide and thus supporting deglutathionylation reactions (5, 6, 51). The functional impact of these qualitatively different mechanisms of glutaredoxin and thioredoxin may be significant, also considering that many "monothiol" glutaredoxins, that is, thioredoxin fold proteins with glutaredoxin homology having only one Cys residue in the active site, have been indeed identified (14). The principal differences between the dithiol and monothiol mechanisms are shown in Figure 2.


ROLE OF THIOREDOXIN AND GLUTAREDOXIN SYSTEMS IN DNA SYNTHESIS

FIG. 1. The principal components of Grx and Trx systems. This slide, made in the 1980s by Dr. Holmgren, schematically shows the Grx and Trx systems as alternative reductants of ribonucleotide reductase, clearly illustrating the glutathione dependence of Grx but with both systems ultimately being propelled by NADPH through either TrxR or glutathione reductase. Trx, thioredoxin; TrxR, thioredoxin reductase; Grx, glutaredoxin; GSH, glutathione; GSSG, glutathione disulfide. (Slide kindly provided by Dr. Holmgren.)



Dithiol mechanism

(Used by both Trxs and Grxs to reduce protein disulfides)



Monothiol mechanism

(Unique for the Grxs, used in the reduction of GSH-mixed disulfides)




FIG. 2. Monothiol and dithiol mechanisms of Grxs. This scheme shows the difference between dithiol (*top*) and monothiol (*bottom*) mechanisms in reduction of Trx or Grx substrates. (Slide kindly provided by Dr. Holmgren.)

Description of Key Finding 3

The links between mammalian thioredoxin reductase and selenium

Dr. Holmgren was the first to purify mammalian thioredoxin reductase to homogeneity, from bovine (21), rat (48) and human tissues, thereby discovering that the enzyme was larger and very different from its bacterial counterpart. Dr. Holmgren was also the first to show that a number of selenium compounds could be directly reduced by mammalian thioredoxin reductase, including selenite (42), selenodiglutathione (4), and selenocystine (3). These findings were all fascinatingly integrated into a selenium-centered system when it was discovered by others that human thioredoxin

reductase itself is a selenoprotein (16, 62). Dr. Holmgren rapidly showed that the selenocysteine residue of the enzyme was indeed needed for its catalytic activity and he revealed molecular mechanisms by which it functioned (67–69). He also discovered additional selenium-containing substrates for the enzyme, such as ebselen (64–66), as well as completely selenocysteine-dependent activities of thioredoxin reductase including reduction of nitrosoglutathione (50) and diverse peroxides (69). He also published the first crystal structure of mammalian thioredoxin reductase (58). Together, these findings intimately link the diverse functions of the complete mammalian thioredoxin system to that of selenium status and thus to the many aspects of selenium in health and disease. This may be also of special importance in




FIG. 3. Links between the mammalian Trx system, selenium metabolism, and cell growth. This scheme summarizes some of the many functions of the Trx system that promote or regulate cell growth. With mammalian TrxR being a selenoprotein, these functions are also selenium dependent. TrxR can further directly reduce several selenium-containing substrates, which intimately links the Trx system to selenium metabolism. Finally, the selenocysteine residue of TrxR is a target for a number of electrophilic anticancer agents, thereby converting the enzyme to a pro-oxidant toxic protein that together with the inhibition of the Trx system may explain some of the anticancer efficacy of such drugs. ROS, reactive oxygen species. (Scheme adopted from a slide kindly provided by Dr. Holmgren.)

relation to cancer growth and anticancer therapy, as summarized in Figure 3.

Other Achievements

Dr. Holmgren has published more than 380 peer-reviewed publications and has clearly had a major impact on research in redox biochemistry. As of today, about 70 of those publications have attracted 100 citations or more (Supplementary Table S1; see www.liebertonline.com/ars). It is difficult to decide what other achievements of Dr. Holmgren should be singled out as his additional accomplishments, in addition to the key findings summarized earlier. However, the following works clearly deserve to be mentioned:

- Characterizing thioredoxin as not only a reductant of ribonucleotide reductase but also a powerful general disulfide reductase, and in the process, introducing insulin as an efficient thioredoxin substrate used in assays of thioredoxin activities (25–27, 33, 59).
- Purifying mammalian thioredoxin and thioredoxin reductase to homogeneity, and developing additional specific assays to measure their activities (21, 48).
- Beyond discovering glutaredoxin (see earlier text) also determining the glutaredoxin structure using nuclear magnetic resonance (NMR) (5, 7) and catalytic mechanism with ribonucleotide reductase from either *E. coli* (5) or mammals (63).
- Purifying and characterizing Grx1, Grx2, Grx3, and Grx4 from *E. coli* (1, 1a, 13, 15, 24, 51, 52, 60).
- Discovering mammalian glutaredoxin 2 and finding that it is an iron-sulfur cluster protein (38, 44–46).
- Discovering that the N-terminal Cys residue in the thioredoxin active site has a low pK_a and thereby explaining the mechanism of thioredoxin-catalyzed disulfide reduction (41), which was further supported by determination of the structure of reduced thioredoxin (8, 9) (at that time the largest solved 2D NMR protein structure). Also discovering differences between the oxidized and reduced protein (29, 39), which underlies the redox regulation by binding of reduced but not oxidized thioredoxin to selected target proteins.
- In a collaborative effort, discovering that thioredoxin regulates photosynthesis (31).
- Characterizing extracellular human thioredoxin and the C-terminally truncated thioredoxin-80 and the effects of these proteins as immunomodulatory cytokines (2, 53–55).

In addition to his many scientific accomplishments, Dr. Holmgren has been also a member of the Nobel Assembly at Karolinska Institutet selecting nobel laureates and of the Swedish Royal Academy of Sciences and recipient of a number of prizes and awards, and he has tutored many prominent scientists in the field of redox biochemistry. Last, but not least, he has vividly entertained many of his colleagues with illustrative recollections of his hunting adventures—his favorite outdoor activity, tracking down moose and wild boars in the Swedish woods aided by his Dachshund dogs. Those dogs have been also loyally joining him in his office. The latest one, *Digger*, is the current dear and friendly pet in the Holmgren laboratory.

Asking Dr. Holmgren to give some words of wisdom for any future scientists in the field, he gives the following statement:

A citation from the French physiologist Claude Bernard has been a great inspiration: “What we know is a great obstacle to learn more about what is yet unknown to us.” Experiments carried out with the highest precision should be analyzed with an unbiased mind. Redox biology has a great future. It has always been a great inspiration to know that redox proteins have been around during evolution from the beginning of life on earth and there is yet so much to discover. Another great inspiration has been to work on selenium and selenoproteins knowing the pioneering work of Jac Berzelius, who discovered and named selenium in 1818 and was a professor of chemistry and pharmacy here at Karolinska Institutet in Stockholm.

Acknowledgments

The author wishes to thank Dr. Arne Holmgren not only for his accomplishments in redox biochemistry and for the impact that his work has had on the redox biochemistry field, but also for being an excellent scientific mentor and for a long friendship. Dr. Holmgren extends his gratitude to the many extremely talented individuals with whom he has been working over the past 45 years. This includes his mentor, Prof. Peter Reichard, and technicians, secretaries, graduate students, postdocs, and collaborators all over the world. Dr. Holmgren acknowledges that it is their contributions and hard work that has formed the basis for the present knowledge about thioredoxin and glutaredoxin systems.

References

1. Åslund F, Ehn B, Miranda VA, Pueyo C, and Holmgren A. Two additional glutaredoxins exist in *Escherichia coli*: glutaredoxin 3 is a hydrogen donor for ribonucleotide reductase in a thioredoxin/glutaredoxin 1 double mutant. *Proc Natl Acad Sci U S A* 91: 9813–9817, 1994.
- 1a. Åslund F, Nordstrand K, Berndt KD, Nikkola M, Bergman T, *et al.* Glutaredoxin-3 from *Escherichia coli*: Amino acid sequence, ^1H and ^{15}N NMR assignments, and structural analysis. *J Biol Chem* 271: 6736–6745, 1996.
- 1b. Atkinson HJ and Babbitt PC. An atlas of the thioredoxin fold class reveals the complexity of function-enabling adaptations. *PLoS Comput Biol* 5: e1000541, 2009.
2. Bizzarri C, Holmgren A, Pekkari K, Chang G, Colotta F, *et al.* Requirements for the different cysteines in the chemotactic and desensitizing activity of human thioredoxin. *Antioxid Redox Signal* 7: 1189–1194, 2005.
3. Björnstedt M, Hamberg M, Kumar S, Xue J, and Holmgren A. Human thioredoxin reductase directly reduces lipid hydroperoxides by NADPH and selenocystine strongly stimulates the reaction via catalytically generated selenols. *J Biol Chem* 270: 11761–11764, 1995.
4. Björnstedt M, Kumar S, and Holmgren A. Selenodiglutathione is a highly efficient oxidant of reduced thioredoxin and a substrate for mammalian thioredoxin reductase. *J Biol Chem* 267: 8030–8034, 1992.
5. Bushweller JH, Åslund F, Wüthrich K, and Holmgren A. Structural and functional characterization of the mutant *Escherichia coli* glutaredoxin (C14—S) and its mixed disulfide with glutathione. *Biochemistry* 31: 9288–9293, 1992.
6. Bushweller JH, Billeter M, Holmgren A, and Wüthrich K. The nuclear magnetic resonance solution structure of the mixed disulfide between *Escherichia coli* glutaredoxin(C14S) and glutathione. *J Mol Biol* 235: 1585–1597, 1994.
7. Bushweller JH, Holmgren A, and Wüthrich K. Biosynthetic ^{15}N and ^{13}C isotope labelling of glutathione in the mixed

- disulfide with *Escherichia coli* glutaredoxin documented by sequence-specific NMR assignments. *Eur J Biochem* 218: 327–334, 1993.
8. Dyson HJ, Gippert GP, Case DA, Holmgren A, and Wright PE. Three-dimensional solution structure of the reduced form of *Escherichia coli* thioredoxin determined by nuclear magnetic resonance spectroscopy. *Biochemistry* 29: 4129–4136, 1990.
 9. Dyson HJ, Holmgren A, and Wright PE. Assignment of the proton NMR spectrum of reduced and oxidized thioredoxin: sequence-specific assignments, secondary structure, and global fold. *Biochemistry* 28: 7074–7087, 1989.
 10. Dyson HJ, Jeng MF, Model P, and Holmgren A. Characterization by ¹H NMR of a C32S,C35S double mutant of *Escherichia coli* thioredoxin confirms its resemblance to the reduced wild-type protein. *FEBS Lett* 339: 11–17, 1994.
 11. Dyson HJ, Jeng MF, Tennant LL, Slaby I, Lindell M, *et al.* Effects of buried charged groups on cysteine thiol ionization and reactivity in *Escherichia coli* thioredoxin: structural and functional characterization of mutants of Asp 26 and Lys 57. *Biochemistry* 36: 2622–2636, 1997.
 12. Dyson HJ, Tennant LL, and Holmgren A. Proton-transfer effects in the active-site region of *Escherichia coli* thioredoxin using two-dimensional ¹H NMR. *Biochemistry* 30: 4262–4268, 1991.
 13. Fernandes AP, Fladvad M, Berndt C, Andresen C, Lillig CH, *et al.* A novel monothiol glutaredoxin (Grx4) from *Escherichia coli* can serve as a substrate for thioredoxin reductase. *J Biol Chem* 280: 24544–24552, 2005.
 14. Fernandes AP and Holmgren A. Glutaredoxins: glutathione-dependent redox enzymes with functions far beyond a simple thioredoxin backup system. *Antioxid Redox Signal* 6: 63–74, 2004.
 15. Fladvad M, Bellanda M, Fernandes AP, Mammi S, Vlamis-Gardikas A, *et al.* Molecular mapping of functionalities in the solution structure of reduced Grx4, a monothiol glutaredoxin from *Escherichia coli*. *J Biol Chem* 280: 24553–24561, 2005.
 16. Gladyshev VN, Jeang K-T, and Stadtman TC. Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. *Proc Natl Acad Sci U S A* 93: 6146–6151, 1996.
 17. Holmgren A. Thioredoxin. 4. Amino acid sequence of peptide B. *Eur J Biochem* 5: 359–365, 1968.
 18. Holmgren A. Thioredoxin. 5. Amino acid sequences of the tryptic peptides of peptide A. *Eur J Biochem* 6: 467–474, 1968.
 19. Holmgren A. Thioredoxin. 6. The amino acid sequence of the protein from *Escherichia coli* B. *Eur J Biochem* 6: 475–484, 1968.
 20. Holmgren A. Hydrogen donor system for *Escherichia coli* ribonucleoside-diphosphate reductase dependent upon glutathione. *Proc Natl Acad Sci U S A* 73: 2275–2279, 1976.
 21. Holmgren A. Bovine thioredoxin system. Purification of thioredoxin reductase from calf liver and thymus and studies of its function in disulfide reduction. *J Biol Chem* 252: 4600–4606, 1977.
 22. Holmgren A. Glutathione-dependent enzyme reactions of the phage T4 ribonucleotide reductase system. *J Biol Chem* 253: 7424–7430, 1978.
 23. Holmgren A. Glutathione-dependent synthesis of deoxyribonucleotides. Characterization of the enzymatic mechanism of *Escherichia coli* glutaredoxin. *J Biol Chem* 254: 3672–3678, 1979.
 24. Holmgren A. Glutathione-dependent synthesis of deoxyribonucleotides. Purification and characterization of glutaredoxin from *Escherichia coli*. *J Biol Chem* 254: 3664–3671, 1979.
 25. Holmgren A. Reduction of disulfides by thioredoxin. Exceptional reactivity of insulin and suggested functions of thioredoxin in mechanism of hormone action. *J Biol Chem* 254: 9113–9119, 1979.
 26. Holmgren A. Thioredoxin catalyzes the reduction of insulin disulfides by dithiothreitol and dihydrolipoamide. *J Biol Chem* 254: 9627–9632, 1979.
 27. Holmgren A. Enzymatic reduction-oxidation of protein disulfides by thioredoxin. *Methods Enzymol* 107: 295–300, 1984.
 28. Holmgren A. Thioredoxin. *Annu Rev Biochem* 54: 237–271, 1985.
 29. Holmgren A. Thioredoxin structure and mechanism: conformational changes on oxidation of the active-site sulfhydryls to a disulfide. *Structure* 3: 239–243, 1995.
 30. Holmgren A, Arnér ESJ, and Berndt K. Thioredoxin. In: *Encyclopedia of Molecular Biology*, edited by Creighton TE. New York: John Wiley & Sons, Inc., 1999, pp. 2535–2538.
 31. Holmgren A, Buchanan BB, and Wolosiuk RA. Photosynthetic regulatory protein from rabbit liver is identical with thioredoxin. *FEBS Lett* 82: 351–354, 1977.
 32. Holmgren A and Karlsson GB. Function of thioredoxin in oxidoreductions and as a subunit of phage-T7 deoxyribonucleic acid polymerase. *Biochem Soc Trans* 6: 50–52, 1978.
 33. Holmgren A and Morgan FJ. Enzyme reduction of disulfide bonds by thioredoxin. The reactivity of disulfide bonds in human choriongonadotropin and its subunits. *Eur J Biochem* 70: 377–383, 1976.
 34. Holmgren A, Perham RN, and Baldesten A. Thioredoxin. 3. Amino acid sequences of the peptic peptides from S-aminoethylated peptide B. *Eur J Biochem* 5: 352–358, 1968.
 35. Holmgren A and Reichard P. Thioredoxin 2: cleavage with cyanogen bromide. *Eur J Biochem* 2: 187–196, 1967.
 36. Holmgren A, Reichard P, and Thelander L. Enzymatic synthesis of deoxyribonucleotides, 8. The effects of ATP and dATP in the CDP reductase system from *E. coli*. *Proc Natl Acad Sci U S A* 54: 830–836, 1965.
 37. Holmgren A, Söderberg BO, Eklund H, and Brändén CI. Three-dimensional structure of *Escherichia coli* thioredoxin-S2 to 2.8 Å resolution. *Proc Natl Acad Sci U S A* 72: 2305–2309, 1975.
 38. Hudemann C, Lonn ME, Godoy JR, Avval FZ, Capani F, *et al.* Identification, Expression Pattern, and Characterization of Mouse Glutaredoxin 2 Isoforms. *Antioxid Redox Signal* 11: 1–14, 2009.
 39. Jeng M-F, Campell AP, Begley T, Holmgren A, Case DA, Wright PE, and Dyson HJ. High-resolution structures of oxidized and reduced *Escherichia coli* thioredoxin. *Structure* 2: 853–868, 1994.
 40. Johansson C, Lillig CH, and Holmgren A. Human mitochondrial glutaredoxin reduces S-glutathionylated proteins with high affinity accepting electrons from either glutathione or thioredoxin reductase. *J Biol Chem* 279: 7537–7543, 2004.
 41. Kallis GB and Holmgren A. Differential reactivity of the functional sulfhydryl groups of cysteine-32 and cysteine-35 present in the reduced form of thioredoxin from *Escherichia coli*. *J Biol Chem* 255: 10261–10265, 1980.
 42. Kumar S, Björnstedt M, and Holmgren A. Selenite is a substrate for calf thymus thioredoxin reductase and thioredoxin and elicits a large non-stoichiometric oxidation of NADPH in the presence of oxygen. *Eur J Biochem* 207: 435–439, 1992.
 43. Laurent TC, Moore EC, and Reichard P. Enzymatic synthesis of deoxyribonucleotides. IV. Isolation and characterization of thioredoxin, the hydrogen donor from *Escherichia coli* B. *J Biol Chem* 239: 3436–3444, 1964.

44. Lillig CH, Berndt C, Vergnolle O, Lonn ME, Hudemann C, et al. Characterization of human glutaredoxin 2 as iron-sulfur protein: a possible role as redox sensor. *Proc Natl Acad Sci U S A* 102: 8168–8173, 2005.
45. Lundberg M, Fernandes AP, Kumar S, and Holmgren A. Cellular and plasma levels of human glutaredoxin 1 and 2 detected by sensitive ELISA systems. *Biochem Biophys Res Commun* 319: 801–809, 2004.
46. Lundberg M, Johansson C, Chandra J, Enoksson M, Jacobsson G, et al. Cloning and expression of a novel human glutaredoxin (Grx2) with mitochondrial and nuclear isoforms. *J Biol Chem* 276: 26269–26275, 2001.
47. Luthman M, Eriksson S, Holmgren A, and Thelander L. Glutathione-dependent hydrogen donor system for calf thymus ribonucleoside-diphosphate reductase. *Proc Natl Acad Sci U S A* 76: 2158–2162, 1979.
48. Luthman M and Holmgren A. Rat liver thioredoxin and thioredoxin reductase: purification and characterization. *Biochemistry* 21: 6628–6633, 1982.
49. Matsuzawa A and Ichijo H. Redox control of cell fate by MAP kinase: physiological roles of ASK1-MAP kinase pathway in stress signaling. *Biochim Biophys Acta* 1780: 1325–1336, 2008.
50. Nikitovic D, and Holmgren A. S-Nitrosoglutathione is cleaved by the thioredoxin system with liberation of glutathione and redox regulating nitric oxide. *J Biol Chem* 271: 19180–19185, 1996.
51. Nordstrand K, Åslund F, Holmgren A, Otting G, and Berndt KD. NMR structure of *Escherichia coli* glutaredoxin 3-glutathione mixed disulfide complex: implications for the enzymatic mechanism. *J Mol Biol* 286: 541–552, 1999.
52. Nordstrand K, Sandstrom A, Åslund F, Holmgren A, Otting G, and Berndt KD. NMR structure of oxidized glutaredoxin 3 from *Escherichia coli*. *J Mol Biol* 303: 423–432, 2000.
53. Pekkari K, Avila-Carino J, Bengtsson Å, Gurunath R, Scheynius A, and Holmgren A. Truncated thioredoxin (Trx80) induces production of interleukin-12 and enhances CD14 expression in human monocytes. *Blood* 97: 3184–3190, 2001.
54. Pekkari K, Avila-Carino J, Gurunath R, Bengtsson A, Scheynius A, and Holmgren A. Truncated thioredoxin (Trx80) exerts unique mitogenic cytokine effects via a mechanism independent of thiol oxidoreductase activity. *FEBS Lett* 539: 143–148, 2003.
55. Pekkari K, Goodarzi MT, Scheynius A, and Holmgren A, Avila-Carino J. Truncated thioredoxin (Trx80) induces differentiation of human CD14+ monocytes into a novel cell type (TAMs) via activation of the MAP kinases p38, ERK, and JNK. *Blood* 105: 1598–1605, 2005.
56. Reichard P. Ribonucleotide reductases: substrate specificity by allostery. *Biochem Biophys Res Commun* 396: 19–23, 2010.
57. Reichard P. To be there when the picture is painted. *Annu Rev Biochem* 64: 1–28, 1995.
58. Sandalova T, Zhong L, Lindqvist Y, Holmgren A, and Schneider G. Three-dimensional structure of a mammalian thioredoxin reductase: Implications for mechanism and evolution of a selenocysteine-dependent enzyme. *Proc Natl Acad Sci U S A* 98: 9533–9538, 2001.
59. Savidge G, Carlebjork G, Thorell B, Hessel B, Holmgren A, and Blomback B. Reduction of factor VIII and other coagulation factors by the thioredoxin system. *Thromb Res* 16: 587–599, 1979.
60. Shi J, Vlamis-Gardikas A, Åslund F, Holmgren A, and Rosen BP. Reactivity of glutaredoxins 1, 2, and 3 from *Escherichia coli* shows that glutaredoxin 2 is the primary hydrogen donor to ArsC-catalyzed arsenate reduction. *J Biol Chem* 274: 36039–36042, 1999.
61. Stryer L, Holmgren A, and Reichard P. Thioredoxin. A localized conformational change accompanying reduction of the protein to the sulfhydryl form. *Biochemistry* 6: 1016–1020, 1967.
62. Tamura T and Stadtman TC. A new selenoprotein from human lung adenocarcinoma cells: Purification, properties, and thioredoxin reductase activity. *Proc Natl Acad Sci U S A* 93: 1006–1011, 1996.
63. Zahedi Avval F and Holmgren A. Molecular mechanisms of thioredoxin and glutaredoxin as hydrogen donors for mammalian s phase ribonucleotide reductase. *J Biol Chem* 284: 8233–8240, 2009.
64. Zhao R and Holmgren A. A novel antioxidant mechanism of ebselen involving ebselen diselenide, a substrate of mammalian thioredoxin and thioredoxin reductase. *J Biol Chem* 277: 39456–39462, 2002.
65. Zhao R and Holmgren A. Ebselen is a dehydroascorbate reductase mimic, facilitating the recycling of ascorbate via mammalian thioredoxin systems. *Antioxid Redox Signal* 6: 99–104, 2004.
66. Zhao R and Masayasu H, Holmgren A. Ebselen: a substrate for human thioredoxin reductase strongly stimulating its hydroperoxide reductase activity and a superfast thioredoxin oxidant. *Proc Natl Acad Sci U S A* 99: 8579–8584, 2002.
67. Zhong L, Arner ES, and Holmgren A. Structure and mechanism of mammalian thioredoxin reductase: the active site is a redox-active selenolthiol/selenenylsulfide formed from the conserved cysteine-selenocysteine sequence. *Proc Natl Acad Sci U S A* 97: 5854–5859, 2000.
68. Zhong L, Arnér ESJ, Ljung J, Åslund F, and Holmgren A. Rat and calf thioredoxin reductase are homologous to glutathione reductase with a carboxyl-terminal elongation containing a conserved catalytically active penultimate selenocysteine residue. *J Biol Chem* 273: 8581–8591, 1998.
69. Zhong L and Holmgren A. Essential role of selenium in the catalytic activities of mammalian thioredoxin reductase revealed by characterization of recombinant enzymes with selenocysteine mutations. *J Biol Chem* 275: 18121–18128, 2000.

Address correspondence to:

Prof. Elias S.J. Arnér

Division of Biochemistry

Department of Medical Biochemistry and Biophysics

Karolinska Institutet

Stockholm SE-171 77

Sweden

E-mail: elias.arnér@ki.se

Date of first submission to ARS Central, March 11, 2011; date of final revised submission, April 05, 2011; date of acceptance, April 07, 2011.

Abbreviations Used

- GSH = glutathione
- GSSG = glutathione disulfide
- NMR = nuclear magnetic resonance
- ROS = reactive oxygen species

